Memo Therapeutics AG, a Schlieren, Switzerland-based innovator in the field of antibody discovery and development, closed a Series B financing round of CHF37m after securing an additional CHF23m.
The round was led by Swisscanto Invest and included Adjuvant Capital, Fresenius Medical Care Ventures, GF Group, Verve Ventures, Vesalius Biocapital and Zürcher Kantonalbank.
The company intends to use the funds to advance clinical development of its neutralizing antibody, MTX-005, targeting BK virus infection in renal transplant patients through Phase 2 clinical development.
Led by Dr. Karsten Fischer, Chief Executive Officer, Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis. The company’s antibody discovery platform uses fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at speed, efficiency, and sensitivity. The platform captures and preserves entire B-cell repertoires from any donor species and any B-cell type in recombinant form for display using mammalian cells. The antibody repertoires are subsequently screened in single-cell format using microfluidic screening technology that can assess millions of candidate antibodies directly in functional assays, resulting in recombinant clonal cell lines expressing monoclonal antibodies (mAbs) with the desired functional properties.
The company’s current pipeline features programs in infectious diseases and immuno-oncology.
Memo Therapeutics is located in Bio-Technopark Zurich, Switzerland.
FinSMEs
16/02/2022